Gene Therapy - Medika Life

Three studies report promising results in the use of cutting-edge genome editing and cellular therapies for hard-to-treat blood disorders and cancers.

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

CATEGORIES

2024 Health Trends: Progress, Challenges, and Opportunities

HPV Urban Legends – From Contagion to Symptoms to Risks to Prevention – There Are More Rare Concerns that Deserve Our Attention

When It Comes to the Future of HLTH – Life Is Not a Las Vegas Roulette Wheel

CAR T-mRNA Therapy For Cardiac Fibrosis: A New Way Forward

LATEST

TRENDING

When It Comes to the Future of HLTH – Life Is Not a Las Vegas Roulette Wheel

Central Dogma has Lost its Dog

The Fluoroscope Serves as a Warning for New Medical Technology

Perhaps, A Braver New World

HPV Urban Legends – From Contagion to Symptoms to Risks to Prevention – There Are More Rare Concerns that Deserve Our Attention

Genome Editing and Cellular Therapies Show Promise for Treating Blood Disorders, Cancers

CAR T-mRNA Therapy For Cardiac Fibrosis: A New Way Forward

2024 Health Trends: Progress, Challenges, and Opportunities

Qatar Genome Research Consortium Reports First and Largest Comprehensive Genetic Association Study in Middle East

Elon Musk, Can You Save Us From Covid 2.0?

EDITORS CHOICE

Perhaps, A Braver New World

2024 Health Trends: Progress, Challenges, and Opportunities

HPV Urban Legends – From Contagion to Symptoms to Risks to Prevention – There Are More Rare Concerns that Deserve Our Attention

Genome Editing and Cellular Therapies Show Promise for Treating Blood Disorders, Cancers

CONNECT WITH US ON SOCIAL MEDIA

Compliance

CORPORATE & MEDIA

Popular categories